Literature DB >> 23946878

Use of drug-eluting stents versus bare-metal stents in Korea: a cost-minimization analysis using population data.

Hae Sun Suh1, Hyun Jin Song, Eun Jin Jang, Jung-Sun Kim, Donghoon Choi, Sang Moo Lee.   

Abstract

OBJECTIVES: The goal of this study was to perform an economic analysis of a primary stenting with drug-eluting stents (DES) compared with bare-metal stents (BMS) in patients with acute myocardial infarction (AMI) admitted through an emergency room (ER) visit in Korea using population-based data.
METHODS: We employed a cost-minimization method using a decision analytic model with a two-year time period. Model probabilities and costs were obtained from a published systematic review and population-based data from which a retrospective database analysis of the national reimbursement database of Health Insurance Review and Assessment covering 2006 through 2010 was performed. Uncertainty was evaluated using one-way sensitivity analyses and probabilistic sensitivity analyses.
RESULTS: Among 513 979 cases with AMI during 2007 and 2008, 24 742 cases underwent stenting procedures and 20 320 patients admitted through an ER visit with primary stenting were identified in the base model. The transition probabilities of DES-to-DES, DES-to-BMS, DES-to-coronary artery bypass graft, and DES-to-balloon were 59.7%, 0.6%, 4.3%, and 35.3%, respectively, among these patients. The average two-year costs of DES and BMS in 2011 Korean won were 11 065 528 won/person and 9 647 647 won/person, respectively. DES resulted in higher costs than BMS by 1 417 882 won/person. The model was highly sensitive to the probability and costs of having no revascularization.
CONCLUSIONS: Primary stenting with BMS for AMI with an ER visit was shown to be a cost-saving procedure compared with DES in Korea. Caution is needed when applying this finding to patients with a higher level of severity in health status.

Entities:  

Keywords:  Costs and cost analysis; Drug-eluting stents; Myocardial infarction; Pharmaceutical economics

Mesh:

Substances:

Year:  2013        PMID: 23946878      PMCID: PMC3740225          DOI: 10.3961/jpmph.2013.46.4.201

Source DB:  PubMed          Journal:  J Prev Med Public Health        ISSN: 1975-8375


  17 in total

1.  Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.

Authors:  Andrew T L Ong; Joost Daemen; Ben A van Hout; Pedro A Lemos; Johanna L Bosch; Ron T van Domburg; Patrick W Serruys
Journal:  Eur Heart J       Date:  2006-11-17       Impact factor: 29.983

2.  Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective.

Authors:  Mattias Neyt; Chris De Laet; Annemieke De Ridder; Hans Van Brabandt
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 3.  Are drug-eluting stents safe in the long term?

Authors:  Philippe Généreux; Roxana Mehran
Journal:  CMAJ       Date:  2008-12-23       Impact factor: 8.262

4.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams
Journal:  Circulation       Date:  2009-11-18       Impact factor: 29.690

Review 5.  A systematic review and economic analysis of drug-eluting coronary stents available in Australia.

Authors:  Sarah J Lord; Kirsten Howard; Felicity Allen; Luke Marinovich; David C Burgess; Richard King; John J Atherton
Journal:  Med J Aust       Date:  2005-11-07       Impact factor: 7.738

Review 6.  Drug-eluting stents: a systematic review and economic evaluation.

Authors:  R A Hill; A Boland; R Dickson; Y Dündar; A Haycox; C McLeod; R Mujica Mota; T Walley; A Bagust
Journal:  Health Technol Assess       Date:  2007-11       Impact factor: 4.014

7.  Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials.

Authors:  Alain J Nordmann; Peter Hengstler; Bernd M Leimenstoll; Thomas Harr; James Young; Heiner C Bucher
Journal:  Eur Heart J       Date:  2004-01       Impact factor: 29.983

Review 8.  Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.

Authors:  Somjot S Brar; Martin B Leon; Gregg W Stone; Roxana Mehran; Jeffrey W Moses; Simerjeet K Brar; George Dangas
Journal:  J Am Coll Cardiol       Date:  2009-05-05       Impact factor: 24.094

9.  One year clinical and six month angiographic results of drug eluting stents for ST elevation acute myocardial infarction: 'real world' comparison between sirolimus- and paclitaxel-eluting stents.

Authors:  Kyung Woo Park; Young-Seok Cho; Jin-Wook Chung; Tae-Jin Yeon; In-Ho Chae; Dong-Ju Choi; Byung-Hee Oh; Young-Bae Park; Woo-Young Chung
Journal:  Int J Cardiol       Date:  2008-01-03       Impact factor: 4.164

10.  Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.

Authors:  Emilio Di Lorenzo; Rosario Sauro; Attilio Varricchio; Giannignazio Carbone; Giuliana Cortese; Michele Capasso; Tonino Lanzillo; Fiore Manganelli; Ciro Mariello; Francesco Siano; Maria Rosaria Pagliuca; Giovanni Stanco; Giuseppe Rosato; Giuseppe De Luca
Journal:  Circulation       Date:  2009-08-31       Impact factor: 29.690

View more
  1 in total

1.  Cost-effectiveness modelling of percutaneous coronary interventions in stable coronary artery disease.

Authors:  Ariel Beresniak; Thibaut Caruba; Brigitte Sabatier; Yves Juillière; Olivier Dubourg; Nicolas Danchin
Journal:  World J Cardiol       Date:  2015-10-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.